Bioprinting certainly will play a major role in the future of medicine. Implantation of 3D printed bones, soft tissue, and eventually entire organs look to be on the horizon. With several companies working on the technology, and the science behind 3D bioprinting making huge strides in recent years, the entire medical field may be in for major disruptions.
Swansea University-based life science technology company 3Dynamic Systems Ltd (3DS) has developed two new additive manufacturing systems, but with a difference. These machines are capable of depositing a range of biologically active and biologically compatible materials. The company is working to fabricate 3D transplantable bone and complex tissue constructs on demand. This exciting breakthrough in tissue engineering technology developed by the company could one day be used to treat severely injured patients. The research has successfully engineered a suitable bone composite and a 3D-Bioprinting technology to make high complexity tissue structures. These have been determined to be optimum materials for producing reliable extra cellular matrix-based tissues.
The first system is the 3Dynamic Alpha Series, which is a single extrusion bone tissue fabrication platform. This machine produces calcium phosphate-based bone for regenerating severe non-stabalised fractures. By accurately depositing a special bone composite in 3D, the correct anatomical geometry is produced. This material is seeded with platelet-derived growth factor which creates the right environment for tissue regeneration by recruiting stem cells that can produce bone and forming a supportive structure, including blood vessels.
The second system is the dual extrusion 3Dynamic Omega Series bioprinter which is used to make three dimensional soft tissue constructs. Currently this is capable of producing heterogeneous tissues which are used for pharmaceutical testing trials. This technique is also being explored as a method for bioprinting different tissues including; muscle, adipose and skin. With this technology, techniques are being developed which could be an effective means toward producing transplantable complex tissues on demand.
3DS’ easy to use technology could see a greater adoption of bioprinting research and further innovation in the short-term by enabling researches in the field to effectively produce experimental tissues and multiple tissue types on demand. As a result the bioprinting technology developed by 3DS could one day transform the field of reconstructive medicine which may lead to direct bio-engineering replacement human tissues on-demand for transplantation. For further information visit bioprintingsystems.com. Let’s hear your thoughts on 3D bioprinting, and these new techniques in the 3Dynamic Systems bioprinting forum thread on 3DPB.com.
You May Also Like
Prodways Q2 Revenues Increase, Machine Sales Up 100%
Prodways (PWG.PA) reported a 54% revenue increase year over year for its second quarter in 2021 as the global economy recovers from the Covid-19 pandemic. Driven by the recovery of...
Continuous Composites Receives $17M for Carbon Fiber 3D Printing
Shortly on the heels of launching a lawsuit against competitor Markforged, Continuous Composites has closed a $17 million Series A financing round. Led by B. Riley Financial subsidiary B. Riley...
3D Printing News Briefs, July 17, 2021: SME, Z3DLAB & CNRS, GKN Additive, FibreTuff & RSNA, Nano Dimension & Hensoldt, ioTech
In today’s 3D Printing News Briefs, we’ll tell you about a rebranded case study award, and then a few stories about 3D printing materials. Finishing up, we’re sharing news about...
3D Printing News Briefs, July 14, 2021: Arash & MakerBot, PostProcess & Fraunhofer IAPT, BOFA & Atome3D, CADS Additive, BCN3D
In today’s 3D Printing News Briefs, we’re talking about a 3D printed hypercar, some partnerships and software, and a 3D printing course. Read on for all the details! Arash 3D...
View our broad assortment of in house and third party products.